Lefamulin … [email protected] Paukner, Susanne 1; Flamm, Robert K
Total Page:16
File Type:pdf, Size:1020Kb
In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia Nabriva Therapeutics 1218 www.nabriva.com Lefamulin … [email protected] Paukner, Susanne 1; Flamm, Robert K. 2; Schuchert, Jason 2; Gelone, Steven P. 3; Sader, Helio S. 2 1 Nabriva Therapeutics, Vienna, Austria; 2 JMI Laboratories, North Liberty, IA, USA; 3 Nabriva Therapeutics, King of Prussia, PA, USA ABSTRACT RESULTS Background: S. aureus (SA) is a well-recognized cause of pneumonia from both the community and hospital A . Lefamulin showed potent antibacterial activity against S. aureus isolates, including resistant isolates 1 S. aureus n settings. The clinical management of SA pneumonia is complicated by the invasive infection it can cause and , Total ( =1,273) (Figure 2, Tables 1 and 2). the high prevalence of methicillin resistance (MR).2 Lefamulin (LEF) is the first semi-synthetic pleuromutilin 1000 Lefamulin . Lefamulin was the most potent compound tested with 99.3% inhibited at a lefamulin concentration antibiotic for IV and oral use in humans and it specifically inhibits bacterial protein synthesis. LEF is currently in Azithromycin Ceftaroline of ≤0.25 mg/L (MIC50/90 values of 0.06/0.12 mg/L). Phase 3 trials for the treatment of community-acquired bacterial pneumonia (CABP). This study investigated the 500 in vitro activity of LEF and comparators against SA strains collected from patients hospitalized with pneumonia in Levofloxacin . The lefamulin activity was not affected by resistance to other antibiotics tested, including macrolides, 2015. Vancomycin tetracyclines, fluoroquinolones, or ß-lactam antibiotics or the nosocomial status of isolates. Number of isolates 0 1,273 unique SA isolates were collected from hospitalized patients with pneumonia worldwide in 28 . Methods: ≤0.03 0.06 0.12 0.25 0.5 1 2 4 >4 31.6% of isolates were MRSA, of which n=139 community-acquired (CA-MRSA) and n=152 were countries (33 sites) in 2015 as part of the SENTRY surveillance program. Isolates included 401 hospital-acquired nosocomial (HA-MRSA). MIC [mg/L] (HA) SA (259 from ICU, 152 from ventilator associated pneumonia, [VAP]). Susceptibility testing was conducted . Lefamulin MIC distributions were similar between subsets, including MSSA vs. MRSA, community- using the CLSI broth microdilution method and susceptibility was interpreted per CLSI 2017 breakpoint criteria. VAP vs. Non-VAP B MRSA vs. MSSA CA-MRSA vs. HA-MRSA ICU vs. Non-ICU acquired vs. nosocomial isolates, ICU vs. non-ICU and VAP vs. non-VAP (Figure 2B). Results: LEF was the most potent compound tested, with 99.7% of all SA isolates being inhibited at a 800 MSSA 200 CA-MRSA 800 S. aureus, 400 S. aureus, . MSSA and MRSA showed lefamulin MIC of 0.06/0.12 mg/L. concentration of ≤0.25 mg/L (MIC values of 0.06/0.12 mg/L) and irrespective of the collection source non-ICU non-VAP 50/90 50/90 600 HA MRSA MRSA 600 S. aureus, (ICU/non-ICU, VAP/non-VAP). 31.6% of isolates (n=402) were MRSA of which 99.3% were inhibited at a LEF S. aureus, . Both CA-SA (n=528; MSSA and MRSA) and HA-SA (n=401) displayed a lefamulin MIC50/90 of VAP 400 ICU 200 concentration of ≤0.25 µg/mL (MIC50/90, 0.06/0.12 mg/L). Susceptibility rates for all SA isolates were >90% for 100 400 0.06/0.12 mg/L MIC50/90. ceftaroline, vancomycin, linezolid and doxycycline. Susceptibility to azithromycin, levofloxacin and clindamycin 200 200 . S. aureus isolates were largely susceptible to doxycycline (97.6%), ceftaroline (93.3%), linezolid was limited, particularly among MRSA (see Table 1). Numberof isolates 0 0 0 0 (99.9%) and vancomycin (100%). ≤0.03 0.06 0.12 0.25 0.5 ≤0.03 0.06 0.12 0.25 0.5 ≤0.03 0.06 0.12 0.25 0.5 ≤0.03 0.06 0.12 0.25 0.5 Conclusion: SA strains collected from patients hospitalized with pneumonia including HAP and VAP were highly . Susceptibility to macrolides, fluoroquinolones and lincosamides was significantly reduced, susceptible to LEF regardless of the resistance phenotype to the other antibiotics tested. Due to its potent MIC [mg/L] MIC [mg/L] MIC [mg/L] MIC [mg/L] particularly among MRSA. activity against resistant SA and the most prevalent typical and atypical respiratory pathogens, as well as the Figure 2. MIC distributions of lefamulin and comparators (A) and lefamulin MIC distribution for . 79.9% of MRSA and 23.9% of MSSA were resistant to azithromycin. availability of IV and oral formulations, LEF has the potential to play a role in the empiric treatment of CABP and various S. aureus subsets (B) supports evaluation in HAP and VAP caused by SA. 77.1% of MRSA and 5.5% of MSSA were resistant to levofloxacin. Table 2. In vitro activity of lefamulin and comparators [mg/L] Table 1. In vitro activity of lefamulin and comparators [mg/L] . 43.0% of MRSA and 3.4% of MSSA were resistant to clindamycin. Organism (n) MIC MIC MIC Range [mg/L] % S a % I a % R a S. aureus, total MSSA MRSA 50 90 99 S. aureus (1,273) (n=1273) (n=871) (n=402) Compound Lefamulin 0.06 0.12 0.12 ≤0.03 - >1 b - - - CONCLUSIONS MIC MIC % S % R % S % R 50 90 Azithromycin 0.5 >4 >4 ≤0.03 - >4 56.6 1.8 41.6 . Lefamulin 0.06 0.12 - - - - Ceftaroline 0.25 1 2 ≤0.06 - 4 93.3 6.6 0.1 Lefamulin displayed potent in vitro activity against this contemporary collection of Azithromycin 0.5 >4 73.9 23.9 19.2 79.9 Clindamycin ≤0.25 >2 >2 ≤0.25 - >2 83.9 0.2 15.9 S. aureus isolates collected from hospitalized patients with pneumonia. Ceftaroline 0.25 1 100.0 0.0 78.9 0.2 Doxycycline ≤0.06 0.25 8 ≤0.06 - >8 97.6 2.2 0.2 . Lefamulin was the most active compound against MRSA and MSSA, including both, Clindamycin ≤0.25 >2 100.0 0.0 57.0 43.0 Erythromycin 0.25 >8 >8 ≤0.06 - >8 56.2 5.1 38.6 community-acquired and nosocomial isolates, irrespective of the resistance phenotype to Doxycycline ≤0.06 0.25 99.4 0.1 93.8 0.2 Levofloxacin 0.25 >4 >4 ≤0.03 - >4 71.2 0.6 28.1 other antibiotic classes including macrolides, fluoroquinolones, tetracyclines or ß-lactam Levofloxacin 0.25 >4 93.8 5.5 22.4 77.1 Linezolid 1 1 2 0.25 - 8 99.9 - 0.1 Oxacillin 0.5 >2 100.0 0.0 0.0 100.0 Oxacillin 0.5 >2 >2 ≤0.25 - >2 68.4 - 31.6 antibiotics. Linezolid 1 2 99.9 0.1 100.0 0.0 Figure 1. Lefamulin Vancomycin 0.5 1 1 ≤0.12 - 2 100.0 0.0 0.0 . These data support the development of lefamulin for infections caused by S. aureus, including Vancomycin 0.5 1 100.0 0.0 100.0 0.0 MRSA (402) CAP, HAP and ABSSSI. Lefamulin 0.06 0.12 0.25 ≤0.03 - >1 INTRODUCTION Azithromycin >4 >4 >4 0.06 - >4 19.2 1.0 79.9 Lefamulin is the first representative of pleuromutilin class in clinical development for systemic Ceftaroline 1 2 2 0.25 - 4 78.9 20.9 0.2 REFERENCES administration. Pleuromutilins inhibit bacterial protein synthesis of Gram-positive and Gram-negative Clindamycin ≤0.25 >2 >2 ≤0.25 - >2 57.0 0.0 43.0 (1) Jain S., et al. NEJM 373, 415-27 (2015) 3,4 Doxycycline ≤0.06 4 8 ≤0.06 - >8 93.8 6.0 0.2 (2) http://ecdc.europa.eu/en/healthtopics/Health care-associated_infections/guidance-infection-preventioncontrol/Pages/ organisms, as well as atypical respiratory pathogens. Lefamulin effectively and selectively inhibits guidance-prevention-control-infections-MRSA.aspx Erythromycin >8 >8 >8 ≤0.06 - >8 18.9 4.7 76.4 bacterial translation by binding to the peptidyl transferase center (PTC) via four H-bonds and other (3) Paukner, et al. AAC 57(9), 4489-4495 (2013) interactions at the A- and P-sites, resulting in an “induced fit.”5,6 Phase 1 and 2 trials have demonstrated Levofloxacin >4 >4 >4 0.06 - >4 22.4 0.5 77.1 (4) Waites, K. B., et al. AAC 61(2)(2017) that IV and oral administration of lefamulin are well tolerated. Furthermore, lefamulin (100 mg or Linezolid 1 1 2 0.25 - 2 100.0 - 0.0 (5) Eyal, Z., et al., Sci Rep 6, 39004 (2016) 150 mg IV q12 hours) showed similar efficacy to IV vancomycin in a clinical Phase 2 trial in patients with Oxacillin >2 >2 >2 >2 - >2 0.0 - 100.0 (6) Paukner, S. and Riedl, R. Cold Spring Harbor Laboratory Perspectives, Antibiotics and Antibiotic Resistance (2016) acute bacterial skin and skin structure infections (ABSSSI).7 Currently lefamulin is in late stage Vancomycin 0.5 1 1 ≤0.12 - 2 100.0 0.0 0.0 (7) Prince, W. T, et al. AAC 57(5), 2087-2094 (2013) a b (8) CLSI, M100(2017) development for the treatment of community-acquired bacterial pneumonia (CABP). Criteria as published by CLSI [2017]; Two of 1,273 isolates showed a lefamulin MIC of >1 mg/L. ID Week 2017, October 4-8, San Diego, CA, USA.